July 30 (Reuters) - Mesoblast Ltd MSB.AX :
* MESOBLAST - INDEPENDENT DSMB SET A DATE FOR EARLY SEPTEMBER TO COMPLETE FIRST INTERIM ANALYSIS OF REMESTEMCEL-L PHASE 3 TRIAL FOR COVID-19 ARDS
* MESOBLAST - ODAC, FDA SCHEDULED MEETING FOR AUG.13, TO REVIEW DATA SUPPORTING BLA FOR APPROVAL OF RYONCIL IN TREATMENT OF SR-AGVHD IN CHILDREN
* MESOBLAST LTD - CASH ON HAND AT END OF QUARTER WAS US$129.3 MILLION